A Response to: Letter to the Editor Regarding “Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults” DOI Creative Commons

Mihaela Georgieva,

Tianyu Sun, Ekkehard Beck

et al.

Infectious Diseases and Therapy, Journal Year: 2024, Volume and Issue: 13(11), P. 2457 - 2459

Published: Sept. 18, 2024

Language: Английский

Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study DOI Creative Commons
Jennifer K Quint, Sabada Dube,

Lucy Carty

et al.

Journal of Infection, Journal Year: 2025, Volume and Issue: 90(3), P. 106432 - 106432

Published: Jan. 31, 2025

Language: Английский

Citations

2
Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review DOI Creative Commons

Manuela H Gschwend,

Anthony M. Marchese, Dirk Poelaert

et al.

Vaccine, Journal Year: 2025, Volume and Issue: 49, P. 126777 - 126777

Published: Jan. 31, 2025

Language: Английский

Citations

1
Letter to the Editor Regarding: “Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults” DOI Creative Commons
Hinpetch Daungsupawong, Viroj Wiwanitkit

Infectious Diseases and Therapy, Journal Year: 2024, Volume and Issue: 13(11), P. 2455 - 2456

Published: Sept. 18, 2024

Language: Английский

Citations

0
A Response to: Letter to the Editor Regarding “Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults” DOI Creative Commons

Mihaela Georgieva,

Tianyu Sun, Ekkehard Beck

et al.

Infectious Diseases and Therapy, Journal Year: 2024, Volume and Issue: 13(11), P. 2457 - 2459

Published: Sept. 18, 2024

Language: Английский

Citations

0